SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNLX - NanoLogix, Incorporated
NNLX 0.00010000.0%Oct 31 9:30 AM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: kphone8/2/2017 11:03:14 AM
   of 78
 

Nanologix Incorporated










NanoLogix N-Assay Bacteria Diagnostic Technology To Be Presented Today at AACC Annual Meeting in San Diego

? ?



The N-Assay Diagnostic is a novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of Deinococcus Bacteria. The following information is being presented today at the American Association for Clinical Chemistry (AACC) 69th Annual Meeting in San Diego:





The significance of the results shown in the presentation cannot be understated, as with the addition of the Deinococcus results listed, the N-Assay now has demonstrated its applicability across a broad spectrum of bacteria which to date include E.coli, Group B Streptococcus, Enterococcus, and Gonorrhea, in addition to the yeast Candida.



You may follow this link to the AACC information website:



aacc.org







NanoLogix Incorporated
Local: 330-534-0800
Email: info@nanologix.com // Website: http://www.nanologix.com/



Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext